Financials
Financial year 2025
Service d'Oncologie Radiothérapie Médecine Nucléaire from Namur, company number BE0888714988, closed financial year 2025 with a result of € 0 after tax. For that financial year Service d'Oncologie Radiothérapie Médecine Nucléaire recorded a gross margin of € 13,575 and equity of € 40,643. Compared with financial year 2024, the result moved from € -5 to € 0. Profitable, and profit is growing. The buffer is growing. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on May 28, 2026.
€ 40,643
▲ 7% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 0
▲ still € 5 loss in 2024
Profit after tax over the fiscal year.
€ 1.3 million
▲ 95% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 3,432.
People and assets in 2025
€ 1,500
▼ 50% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 3.3 million
▲ 12% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 21,715
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 16,687 | € 14,552 | € 13,049 | € 13,575 | ▲ 4% |
| Profit after taxes | € -7 | € 3 | € -5 | € 0 | ▲ € 5 |
| Equity | € 33,926 | € 37,512 | € 37,955 | € 40,643 | ▲ 7% |
| Total debts | € 1,108,573 | € 1,567,096 | € 2,928,563 | € 3,295,437 | ▲ 13% |
| Cash | € 54,541 | € 70,295 | € 653,368 | € 1,275,566 | ▲ 95% |
| Retained profit | € 3,433 | € 3,436 | € 3,431 | € 3,432 | |
| Balance sheet total | € 1,142,498 | € 1,604,608 | € 2,966,518 | € 3,336,079 | ▲ 12% |
Key figures of Service d'Oncologie Radiothérapie Médecine Nucléaire, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to Service d'Oncologie Radiothérapie Médecine Nucléaire?
What happened at Service d'Oncologie Radiothérapie Médecine Nucléaire in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- BEVERGAM SRL stepped down as director. NBB
- DOCTEUR GABRIËL SRL stepped down as director. NBB
- VANHAUDENARDE ONCOLOGIE SRL stepped down as director. NBB
- New annual accounts for financial year 2025: profit of € 0. Source: NBB ↗
- BEVERGAM SRL became a director. NBB
- DOCTEUR GABRIËL SRL became a director. NBB
- VANHAUDENARDE ONCOLOGIE SRL became a director. NBB
- New establishment in Namur. KBO
In short
From € 7 loss in 2022 to € 0 profit in 2025.
Paid € 45,864 in corporate taxes since 2022.
Best year ever: 2023, with € 3 profit.
A new publication or filing at Service d'Oncologie Radiothérapie Médecine Nucléaire? We notify you, reason included.
Follow Service d'Oncologie Radiothérapie Médecine NucléaireDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of NUCLEARIS I.M., CABINET MEDICAL MOSE, BEVERGAM, JC GOEMINNE, CABINET MEDICAL HENRIET-MOURIN, Stéphanie Deheneffe Radiothérapie comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
Service d'Oncologie Radiothérapie Médecine NucléaireThe shares are held by NUCLEARIS I.M. (5.5%), CABINET MEDICAL MOSE (5.5%), BEVERGAM (5.3%), JC GOEMINNE (4.7%), CABINET MEDICAL HENRIET-MOURIN (4.4%) and Stéphanie Deheneffe Radiothérapie (0.1%).
Directors
According to the 2025 annual accounts
Managing director · represented by Bernard WILLEMART
since 2024 · until 2029
Director · represented by Stéphanie GABRIËL
since 2024 · until 2029
Director · represented by Vincent VANHAUDENARDE
since 2024 · until 2029
Shareholders
5.5%
5.5%
5.3%
4.7%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Chaussée de Dinant(WP) 894
5100 Namur
Place Louise Godin 15
5000 Namur
Active since 12 April 2007
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 2 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0888.714.988
- VAT number
- BE 0888.714.988
- Registered office
- Chaussée de Dinant(WP) 894, 5100 Namur
- Names & denominations
- Service d'Oncologie Radiothérapie Médecine Nucléaire
- Enterprise type
- Rechtspersoon
- Legal form
- Cooperative company
- Legal situation
- Normale toestand
- Start date
- 12 April 2007
- Peppol
- Active · Active since 23 Jan 2026
- Activities · NACE
Activiteiten van medische beeldvorming en medische laboratoria
Activiteiten van medische laboratoria